Corvus Pharma Gets FDA's Fast-Track for Lymphoma Treatment
By Dean Seal
Corvus Pharmaceuticals said federal regulators have granted fast-track designation to its treatment for relapsed or refractory peripheral T cell lymphoma.
The clinical-stage biopharmaceutical company said Thursday that the Food and Drug Administration granted the special status to soquelitinib for the treatment of T cell lymphoma patients who have already had at least two lines of systemic therapy.
The FDA's fast-track designation facilitates development and expedites the review of drugs that treat serious or life-threatening conditions and have the potential to fill unmet medical needs.
The regulator previously granted soquelitinib orphan-drug designation, which is given to drugs that show promise for potentially treating rare, or orphan, diseases that have fewer than 200,000 cases a year in the U.S.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
August 01, 2024 09:07 ET (13:07 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
6 Top-Performing Large-Growth Funds
-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Morningstar’s Guide to Investing in Stocks
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
United States